Gene therapy company uniQure NV has named Matthew Kapusta its new Chief Executive Officer. Kapusta has been interim CEO since September and also served as Chief Financial Officer for the last two years. 

The Europan Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended four biologics, among them three biosimilars, one monoclonal antibody as well as two targeted therapies for EU market authorisation.

Neurology specialist Celgene has nailed down access to Evotec’s induced pluripotent stem cell (iPSC) platform for screening of compounds against neurodegenerative diseases.

Among other appointments, BASF has named Melanie Maas-Brunner as new President Nutrition and Health, effective April 1, 2017. Previously, Maas-Brunner held the position of Senior Vice President Performance Materials Europe.

Drug discovery company Confo Therapeutics has appointed John Edward Berriman as non-executive director and chairman of the board of directors. Berriman is set to take his seat on the board December 21.

Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit.

Antifungal drug developer F2G Ltd has appointed distinguished research scientist John Rex to the position of Chief Medical Officer.

At the beginning of October, Isabel De Paoli assumed the position of Chief Strategy Officer at German healthcare company Merck GmbH. She will head the Group Strategy and Transformation Function, which has just been created.

Finnish theranostics specialist Orion Corporation is set to fill its oncology pipeline through a drug development alliance. 

Dutch-German molecular diagostics specialist Curetis has bagged debt finanancing from the European Investment Bank (EIB) to expand its automated multiplex PCR platform Univero. The company will receive €10m immediately. Further €15m are milestone-dependent.